Nevirapine and mulitvitamins — Competitive Intelligence Brief

Nevirapine and mulitvitamins (Nevirapine and mulitvitamins) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: non-nucleoside reverse transcriptase inhibitor. Area: Infectious Disease.

phase 3 non-nucleoside reverse transcriptase inhibitor reverse transcriptase Infectious Disease Small molecule

Target snapshot

Nevirapine and mulitvitamins (Nevirapine and mulitvitamins) — National Institute of Allergy and Infectious Diseases (NIAID). Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nevirapine and mulitvitamins TARGET	Nevirapine and mulitvitamins	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	non-nucleoside reverse transcriptase inhibitor	reverse transcriptase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
Nucleos(t)tide analogues	Nucleos(t)tide analogues	King Abdullah International Medical Research Center	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase; viral polymerase
Didanosine (enteric-coated)	Didanosine (enteric-coated)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (non-nucleoside reverse transcriptase inhibitor class)

1. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class